Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis.

Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, Madaio MP, Bottinger EP, Davidson A.

J Immunol. 2008 Feb 1;180(3):1938-47. Erratum in: J Immunol. 2008 Mar 1;180(5):3613. Madaio, Michael M [corrected to Madaio, Michael P].

2.

Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition.

Schiffer L, Sinha J, Wang X, Huang W, von Gersdorff G, Schiffer M, Madaio MP, Davidson A.

J Immunol. 2003 Jul 1;171(1):489-97. Erratum in: J Immunol. 2003 Aug 1;171(3):1610. Von Gonsdorff Gero [corrected to von Gersdorff Gero].

3.

A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis.

Bethunaickan R, Berthier CC, Ramanujam M, Sahu R, Zhang W, Sun Y, Bottinger EP, Ivashkiv L, Kretzler M, Davidson A.

J Immunol. 2011 Apr 15;186(8):4994-5003. doi: 10.4049/jimmunol.1003010. Epub 2011 Mar 16.

4.

Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.

Lourenço EV, Wong M, Hahn BH, Palma-Diaz MF, Skaggs BJ.

Arthritis Rheumatol. 2014 Mar;66(3):674-85. doi: 10.1002/art.38259.

5.

CCR1 inhibition ameliorates the progression of lupus nephritis in NZB/W mice.

Bignon A, Gaudin F, Hémon P, Tharinger H, Mayol K, Walzer T, Loetscher P, Peuchmaur M, Berrebi D, Balabanian K.

J Immunol. 2014 Feb 1;192(3):886-96. doi: 10.4049/jimmunol.1300123. Epub 2013 Dec 23.

6.

IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice.

Liu Z, Bethunaickan R, Huang W, Ramanujam M, Madaio MP, Davidson A.

J Immunol. 2011 Aug 1;187(3):1506-13. doi: 10.4049/jimmunol.1004142. Epub 2011 Jun 24.

7.

Anti-tumor necrosis factor α treatment of interferon-α-induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation.

Bethunaickan R, Sahu R, Liu Z, Tang YT, Huang W, Edegbe O, Tao H, Ramanujam M, Madaio MP, Davidson A.

Arthritis Rheum. 2012 Oct;64(10):3399-408. doi: 10.1002/art.34553.

8.

Identification of stage-specific genes associated with lupus nephritis and response to remission induction in (NZB × NZW)F1 and NZM2410 mice.

Bethunaickan R, Berthier CC, Zhang W, Eksi R, Li HD, Guan Y, Kretzler M, Davidson A.

Arthritis Rheumatol. 2014 Aug;66(8):2246-2258. doi: 10.1002/art.38679.

9.

Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice.

Lui SL, Yung S, Tsang R, Zhang F, Chan KW, Tam S, Chan TM.

Lupus. 2008 Apr;17(4):305-13. doi: 10.1177/0961203307088289.

PMID:
18413412
10.

Nucleosomes contribute to increase mesangial cell chemokine expression during the development of lupus nephritis.

Kanapathippillai P, Hedberg A, Fenton CG, Fenton KA.

Cytokine. 2013 May;62(2):244-52. doi: 10.1016/j.cyto.2013.03.016. Epub 2013 Apr 4.

PMID:
23561928
11.

Macrophage depletion ameliorates nephritis induced by pathogenic antibodies.

Chalmers SA, Chitu V, Herlitz LC, Sahu R, Stanley ER, Putterman C.

J Autoimmun. 2015 Feb;57:42-52. doi: 10.1016/j.jaut.2014.11.007. Epub 2014 Dec 29.

12.

Dependence of Glomerulonephritis Induction on Novel Intraglomerular Alternatively Activated Bone Marrow-Derived Macrophages and Mac-1 and PD-L1 in Lupus-Prone NZM2328 Mice.

Sung SJ, Ge Y, Dai C, Wang H, Fu SM, Sharma R, Hahn YS, Yu J, Le TH, Okusa MD, Bolton WK, Lawler JR.

J Immunol. 2017 Apr 1;198(7):2589-2601. doi: 10.4049/jimmunol.1601565. Epub 2017 Feb 20.

PMID:
28219886
13.

Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis.

Berthier CC, Bethunaickan R, Gonzalez-Rivera T, Nair V, Ramanujam M, Zhang W, Bottinger EP, Segerer S, Lindenmeyer M, Cohen CD, Davidson A, Kretzler M.

J Immunol. 2012 Jul 15;189(2):988-1001. doi: 10.4049/jimmunol.1103031. Epub 2012 Jun 20.

14.

Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis.

Pérez de Lema G, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, Schlöndorff D.

J Am Soc Nephrol. 2001 Jul;12(7):1369-82.

15.

Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis.

Quezada SA, Eckert M, Adeyi OA, Schned AR, Noelle RJ, Burns CM.

Arthritis Rheum. 2003 Sep;48(9):2541-54.

16.

The role of aldosterone blockade in murine lupus nephritis.

Monrad SU, Killen PD, Anderson MR, Bradke A, Kaplan MJ.

Arthritis Res Ther. 2008;10(1):R5. doi: 10.1186/ar2353. Epub 2008 Jan 15.

17.

Lupus nephritis: the evolving role of novel therapeutics.

Rovin BH, Parikh SV.

Am J Kidney Dis. 2014 Apr;63(4):677-90. doi: 10.1053/j.ajkd.2013.11.023. Epub 2014 Jan 7. Review.

18.

DNA-dependent activator of interferon-regulatory factors (DAI) promotes lupus nephritis by activating the calcium pathway.

Zhang W, Zhou Q, Xu W, Cai Y, Yin Z, Gao X, Xiong S.

J Biol Chem. 2013 May 10;288(19):13534-50. doi: 10.1074/jbc.M113.457218. Epub 2013 Apr 3.

19.

Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice.

Lui SL, Tsang R, Chan KW, Zhang F, Tam S, Yung S, Chan TM.

Nephrol Dial Transplant. 2008 Sep;23(9):2768-76. doi: 10.1093/ndt/gfn216. Epub 2008 Apr 29.

PMID:
18445640
20.

Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice.

Yung S, Zhang Q, Chau MK, Chan TM.

Autoimmunity. 2015;48(7):471-87. doi: 10.3109/08916934.2015.1054027. Epub 2015 Jun 23.

PMID:
26099989

Supplemental Content

Support Center